The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global 3D bioprinting market was valued at US$ 869 Million in 2021.
We expect the global 3D bioprinting market to exhibit a CAGR of 16.85% during 2022-2027.
The increasing application of 3D bioprinting for liver modeling and development of medical implants, is
currently catalyzing the global 3D bioprinting market.
The sudden outbreak of the COVID-19 pandemic has led to the rising use for 3D bioprinting as a rapid
fabrication method for designing and producing preventive, diagnostic, and treatment devices to
combat the spread of coronavirus infection.
Based on the component, the global 3D bioprinting market can be segmented into 3D bioprinters,
scaffolds, and biomaterials. Among these, 3D bioprinters, including syringe/extrusion bioprinting
currently holds the majority of the total market share.
Based on the application, the global 3D bioprinting market has been divided into research and clinical.
Currently, research exhibits a clear dominance in the market.
Based on the end user, the global 3D bioprinting market can be categorized into hospitals, research
organization and academic institutes, and biopharmaceuticals companies. Among these,
biopharmaceuticals companies currently account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin
America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global 3D bioprinting market include 3D Systems Inc., Aspect
Biosystems Ltd., Cellink, Cyfuse Biomedical K.K., EnvisionTEC GmbH (Desktop Metal Inc.), GeSiM –
Gesellschaft für Silizium-Mikrosysteme mbH, Materialise, Organovo Holdings Inc., Poietis, RegenHU, and
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at